Turtlemint Fintech’s IPO opened to a cautious response, with modest early subscription and stronger participation from retail investors. Mu...

The IPO comprises a fresh issue worth Rs 660.7 crore and an offer for sale (OFS) of Rs 221.9 crore, taking the total issue size to about Rs...

Indian drug giant Aurobindo Pharma is set for a major US expansion. The company has received crucial antitrust clearance from the US Federa...

The U.S. Federal Trade Commission (FTC) has mandated that Aurobindo Pharma must sell off four specific drug products. This action is a cond...

Fund Manager Christy Mathai sees easing war-driven inflation fears, expecting a shorter earnings hit. He's selectively adding to his portfo...

Zydus Lifesciences' shares dipped 2% after completing the $166.4 million acquisition of US-based Assertio Holdings Inc. The deal, finalized...

Indian equities extended gains for a third straight session, with Sensex and Nifty rising on optimism over the Iran-US peace framework and ...

Indian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...

Indian pharma is shifting from generics to innovation. This transformation, extending to 2035, is creating significant new opportunities. C...

Markets rallied sharply as easing US–Iran tensions and softer crude prices boosted sentiment. Sensex and Nifty surged 2%, adding Rs 10 lakh...

Several states have constituted dedicated multi-member teams to ensure no facility slips through the cracks before a GMP Certificate is iss...

Indian equities witnessed sharp swings before ending lower amid expiry-day volatility and rising geopolitical concerns. Profit booking in b...

AstraZeneca Pharma India has secured approval from India's drug regulator for its smart chemotherapy drug Enhertu. This allows for its impo...

Indian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...

The landscape of India's anti-obesity drug market has reached a point of refinement. While there are affordable generic options, their upta...

Domestic equities ended lower amid global uncertainty and caution ahead of key US inflation data. Despite market weakness, analysts remain ...

Pharma industry officials say the revised Schedule M regulations could require Rs 10-15 crore per facility in upgrades, while talent shorta...